Galectin Therapeutics Inc.
GALT
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.23M | 5.80M | 5.68M | 5.57M | 5.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.27M | 20.09M | 29.15M | 34.02M | 40.68M |
| Operating Income | -16.27M | -20.09M | -29.15M | -34.02M | -40.68M |
| Income Before Tax | -26.25M | -30.84M | -37.30M | -40.34M | -45.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.25 | -30.84 | -37.30 | -40.34 | -45.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.25M | -30.84M | -37.30M | -40.34M | -45.19M |
| EBIT | -16.27M | -20.09M | -29.15M | -34.02M | -40.68M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.41 | -0.49 | -0.59 | -0.64 | -0.72 |
| Normalized Basic EPS | -0.25 | -0.30 | -0.37 | -0.40 | -0.45 |
| EPS Diluted | -0.41 | -0.49 | -0.59 | -0.64 | -0.72 |
| Normalized Diluted EPS | -0.25 | -0.30 | -0.37 | -0.40 | -0.45 |
| Average Basic Shares Outstanding | 258.18M | 255.60M | 253.60M | 251.68M | 250.46M |
| Average Diluted Shares Outstanding | 258.18M | 255.60M | 253.60M | 251.68M | 250.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |